Clinical case of factitious hypoglycemia
https://doi.org/10.21518/2079-701X-2020-7-130-136
Abstract
Hypoglycemic syndrome (HGS) is a significant decrease glucose in blood, manifested by neurological symptoms, and stopped by the introduction of glucose. Among the many causes of HGS the special place is taken by the factitious hypoglycemia, as one of the variants of Munchausen syndrome. Hypoglycemia in such cases is achieved by the intentional introduction of hypoglycemic drugs. The most commonly used medications are sulfonylurea derivatives, which are affordable, inexpensive and legal. The close collaboration of clinicians with the laboratory service plays a key role in the diagnosis of factitious hypoglycemia. Since the results of biochemical and hormonal analyzes in patients with hypoglycemia due to reception of oral hypoglycemic medications and pancreatogenous HGS are identical, the only way to differentiate these conditions is by detection of insulin secretagogue substances in the blood (or urine).
The determination of oral hypoglycemic medications in cases of suspicion of artificial reception is not implemented in Russia. Factitious hypoglycemia in most cases is the diagnosis of exclusion, and its confirmation if often based on detection of medications among the personal effects of patient. This is a significant difficulty given the ethical standards. However, since 2018 we conduct in our Centre the determination of 7 oral hypoglycemic medications (glibenclamide, gliquidone, gliclazide, glimepiride, glipizide, nateglinide and repaglinide) in patient’s blood using the liquid chromatography–tandem mass spectrometry (LC-MS). This article presents a clinical case of a patient without diabetes mellitus taking glibenclamide and detection of this drug using highly selective LC-MS.
About the Authors
M. Yu. Yukina
National Medical Research Center of Endocrinology
Russian Federation
Russian Federation
Marina Y. Yukina, Cand. of Sci. (Med.), leading researcher of the Department of Therapeutic Endocrinology
11, Dmitry Ulyanov St., Moscow, 117036, Russia
N. F. Nuralieva
National Medical Research Center of Endocrinology
Russian Federation
Russian Federation
Nurana F. Nuralieva, researcher of the Department of Therapeutic Endocrinology
11, Dmitry Ulyanov St., Moscow, 117036, Russia
E. A. Troshina
National Medical Research Center of Endocrinology
Russian Federation
Russian Federation
Ekaterina A. Troshina, Corresponding Member of the RAS, Dr. of Sci. (Med.), professor, head of the Department of Therapeutic Endocrinology
11, Dmitry Ulyanov St., Moscow, 117036, Russia
V. A. Ioutsi
National Medical Research Center of Endocrinology
Russian Federation
Russian Federation
Vitaliy A. Ioutsi, Cand. of Sci. (Chem.), head of the Laboratory for Metabolomics
11, Dmitry Ulyanov St., Moscow, 117036, Russia
References
1. Kinns H., Housley D., Freedman D.B. Review Article. Munchausen syndrome and factitious disorder: the role of the laboratory in its detection and diagnosis. Ann Clin Biochem. 2013;50(3):194–203. doi: 10.1177/0004563212473280.
2. Ameh V., Speak N. Factitious hypoglycaemia in a nondiabetic patient. European Journal of Emergency Medicine. 2008;15(1):59–60. doi: 10.1097/MEJ.0b013e3282aa3f70.
3. Yukina M.Y., Nuralieva N.F., Troshina E.A., Kuznetsov N.S., Platonova N.M. The hypoglycemic syndrome (insulinoma): pathogenesis, etiology, laboratory diagnosis (review, part 1). Problemy Endocrinologii = Problems of Endocrinology. 2017;63(4):245–256. (In Russ.) doi: 10.14341/probl2017634245-256.
4. Nirantharakumar K., Marshall T., Hodson J. et al. Hypoglycemia in Non-Diabetic In-Patients: Clinical or Criminal? PLoS ONE. 2012;7(7):e40384. doi: 10.1371/journal.pone.0040384.
5. Loukianova I.Y., Shishkin A.N., Baranov D.Z., Semenova O.I. Differential diagnostics of hypoglycemia as a symptom of “Munchausen syndrome”: a clinical case. Juvenis scientia. 2017;(1):11–15. (In Russ.) Available at: https://www.jscientia.org/2017-1-003.
6. Guedes B.V., Acosta C.S., Cabrera F. et al. Factitious Hypoglycemia in Pregnancy in a Patient With Type 2 Diabetes. Obstet Gynecol. 2014;124(2):456–458. doi: 10.1097/AOG.0000000000000138.
7. Wazaify M., Abushams L., Van Hout M.C. Abuse of sulfonylureas: Is factitious hypoglycemia a cause for concern? Int J Clin Pharm. 2019;41(1):3–5. doi: 10.1007/s11096-018-0767-9.
8. Giurgea I., Ulinski T., Touati G. et al. Factitious Hyperinsulinism Leading to Pancreatectomy: Severe Forms of Munchausen Syndrome by Proxy. Pediatrics. 2005;116(1):e145–e148. doi: 10.1542/peds.2004-2331.
9. Cryer P.E., Axelrod L., Grossman A.B. et al. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(3):709–728. doi: 10.1210/jc.2008-1410.
10. Agin A., Charrie A., Chikh K. et al. Fast test: clinical practice and interpretation. Ann Endocrinol (Paris). 2013;74(3):174–184. doi: 10.1016/j.ando.2013.05.003.
11. Shestakova M.V. Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL. Sakharny Diabet = Diabetes Mellitus. 2011;14(4):75–80. (In Russ.) doi: 10.14341/2072-0351-5822.
12. White J.R. A Brief History of the Development of Diabetes Medications. Diabetes Spectrum. 2014;27(2):82–86. doi: 10.2337/diaspect.27.2.82.
13. Glinkina I.V. Sulphonylurea Derivatives In The Treatment Of Type 2 Diabetes Mellitus At Current Stage. Farmateka. 2009;(12):35–40. (In Russ.) Available at: https://lib.medvestnik.ru/apps/lib/assets/uploads/pharmateca/PDF/7561.pdf.
14. Yates C., Neoh S., Konpa A., Fullinfaw R., Colman P. Factitious hypoglycaemia. Internal Medicine Journal. 2009;39(12):е15–е16. doi: 10.1111/j.1445-5994.2009.02100.x.
15. Hoizey G., Lamiable D., Trenque T. et al. Identification and Quantification of 8 Sulfonylureas with Clinical Toxicology Interest by Liquid Chromatography – Ion-Trap Tandem Mass Spectrometry and Library Searching. Clin Chem. 2005;51(9):1666–1672. doi: 10.1373/clinchem.2005.050864.
16. Liang X.R., Dai X.J., Zhang Y.F., Ding J.F., Chen X.Y., Zhong D.F. Liquid chromatography- tandem mass spectrometry simultaneous determination of repaglinide and metformin in human plasma and its application to bioequivalence study. Yao Xue Xue Bao. 2013;48(4):547–553. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23833944.
17. Chunduri H.R.B., Dannana G.S. Development and validation of LC-MS/MS method for simultaneous quantification of metformin and nateglinide in human plasma and its application to a pharmacokinetic study. World journal of pharmacy and pharmaceutical sciences. 2016;5(2):651–667. Available at: https://storage.googleapis.com/journal-uploads/wjpps/article_issue/1454137119.pdf.
18. Gama R., Teale J.D., Marks V. Best practice No 173: clinical and laboratory investigation of adult spontaneous hypoglycaemia. J Clin Pathol. 2003;56(9):641–646. doi: 10.1136/jcp.56.9.641.
19. Jensen R.T., Cadiot G., Brandi M.L. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98–119. Available at: https://www.enets.org/d.f.187.pdf.
20. Bem-Chetrit E., Melmed R.N. Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. Journal of Internal Medicine. 1998;244(2):175–178. doi: 10.1046/j.1365-2796.1998.00325.x.
Review
For citations:
Yukina MY, Nuralieva NF, Troshina EA, Ioutsi VA. Clinical case of factitious hypoglycemia. Meditsinskiy sovet = Medical Council. 2020;(7):130-136. (In Russ.) https://doi.org/10.21518/2079-701X-2020-7-130-136
Views:
1168
Email this article 